🇺🇸 FDA

P1 · Therapeutic area intelligence

Obesity & metabolic patent intelligence

GLP-1, GIP/GLP-1, diabetes, and metabolic disease patents — critical for obesity market IP tracking.

Patents
276

Quick answer

276 US pharmaceutical patents in our index match Obesity & metabolic title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11291658

    Use of gaboxadol in the treatment of diabetes and related conditions

    OVID THERAPEUTICS INC. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11274303

    Olmalinc as a diagnostic and therapeutic target for NAFLD, NASH, metabolic syndrome, and hepatic fibrosis

    The United States Government represented by the Department of Veterans Affairs · Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11207361

    AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11186611

    Peptide with anti-obesity and anti-diabetes activity and use thereof

    CAREGEN CO., LTD. · Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11179370

    Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

    Jenrin Discovery, LLC · Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11180452

    Methods and compositions for selectively inhibiting pathogenic microbes

    The Board of Regents of the University of Oklahoma · Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11166962

    Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11166949

    NURR1 activation in the treatment of metabolic disorders and as an exercise mimetic

    The Board of Regents of the University of Texas System · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11122832

    Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise

    Nature's Sunshine Products, Inc. · Granted Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11116740

    Methods for use in support of planned supplement and food ingredient products for diagnosis and treatment of metabolic syndrome

    United States of America as represented by the Secretary of the Air Force · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11096910

    Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease

    The Board of Regents of the University of Texas System · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11090311

    Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11046785

    Compositions and methods for treatment of diabetic macular edema

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11040055

    Method of treating diabetic retinopathy or wet type adult macular degeneration

    China Medical University · Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11013818

    Library of pH responsive polymers and nanoprobes thereof

    The Board of Regents of the University of Texas System · Granted Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10980861

    Glucokinase activator compositions for the treatment of diabetes

    VTV THERAPEUTICS LLC · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10973862

    Bifidobacterium longum for treating obesity and associated metabolic disorders

    PrecisionBiotics Group Limited · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10968231

    Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10967051

    Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof

    Oramed Ltd. · Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10952980

    GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

    The Regents of the University of California · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10941187

    GLP-1, exendin-4, peptide analogs and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10918738

    Method of treating type I diabetes using an AAV vector encoding uracortin 2

    The Regents of the University of California · Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10912846

    Molecular probes for chemiluminescence imaging and in vivo detection of target molecules

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10858323

    HDAC inhibitors for the treatment of diabetic peripheral neuropathy

    Regenacy Pharmaceuticals, Inc. · Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10835505

    Oral pharmaceutical formulation for weight loss, diabetes and related disorders

    Aardvark Therapeutics, Inc. · Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10813918

    Use of Gaboxadol in the treatment of diabetes and related conditions

    OVID THERAPEUTICS INC. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10800782

    Inhibitors of cellular metabolic processes

    Agios Pharmaceuticals, Inc. · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10780106

    Method for treating NASH accompanied by fibrosis using Cl-IB-MECA

    CAN-FITE BIOPHARMA LTD. · Granted Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10738081

    Peptide with anti-obesity and anti-diabetes activity and use thereof

    CAREGEN CO., LTD. · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10723777

    Peptide having anti-obesity and anti-diabetes efficacy and use thereof

    CAREGEN CO., LTD. · Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10702525

    Pyrimidine derivatives as anti-diabetic agents

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Jul 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10682393

    Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions

    United States Department of Veteran Affairs · Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10668062

    Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes

    Lixte Biotechnology, Inc. · Granted Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10653800

    Oligonucleotide-based probes for detection of bacterial nucleases

    INTEGRATED DNA TECHNOLOGIES, INC. · Granted Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10646537

    Traditional Chinese medicine for treating abdominal obesity

    INFINITUS (CHINA) COMPANY LTD. · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10626145

    Peptide with anti-obesity and anti-diabetes activity and use thereof

    CAREGEN CO., LTD. · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10617673

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10588943

    Glucokinase activator compositions for the treatment of diabetes

    VTV THERAPEUTICS LLC · Granted Tue Mar 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10583145

    Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10570185

    Method to detect autoantibody reactivity for deamidated insulin autoantigen in diabetes

    Northwestern University · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10537528

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds

    The Regents of the University of California · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10537537

    Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10507284

    Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type I diabetes applications

    The Regents of the University of California · Granted Tue Dec 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10500271

    Compositions and methods for self-adjuvanting vaccines against microbes and tumors

    The Regents of the University of California · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10449171

    Compositions and methods for diagnosis and treatment of metabolic syndrome

    The United States of America, as represented by Secretary of the Navy · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10449170

    Compositions for diagnosis and treatment of type 2 diabetes

    The United States of America, as represented by Secretary of the Navy · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10442856

    Methods of treating obesity with anti-ANGPTL8 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10434078

    GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

    The Regents of the University of California · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Obesity & metabolic patents are indexed?

276 patents match our Obesity & metabolic classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.